3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
12
OTHER_GOV
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Carcinoma, Non-Small-Cell Lung
497
Neoplasms
302
Breast Neoplasms
294
Colorectal Neoplasms
228
Neoplasm Metastasis
194
Prostatic Neoplasms
175
Ovarian Neoplasms
173
Lung Neoplasms
159
Multiple Myeloma
158
Recurrence
131
Melanoma
125
Pancreatic Neoplasms
115
Squamous Cell Carcinoma of Head and Neck
104
Stomach Neoplasms
102
Leukemia, Myeloid, Acute
101
Endometrial Neoplasms
101
Small Cell Lung Carcinoma
88
Leukemia, Lymphocytic, Chronic, B-Cell
87
Triple Negative Breast Neoplasms
84
Lymphoma, Non-Hodgkin
84
Carcinoma, Renal Cell
83
Carcinoma, Hepatocellular
79
Urinary Bladder Neoplasms
77
Lymphoma, Large B-Cell, Diffuse
74
Lymphoma, Follicular
68
Advanced Solid Tumors
66
Lymphoma
62
Parkinson Disease 4, Autosomal Dominant Lewy Body
61
Glioblastoma
58
Head and Neck Neoplasms
56
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Monoclonal Gammopathy of Undetermined Significance
×
90 days
×
Clear all
NCT06140524
2026-06-04
LINKER-MGUS1
Regeneron Pharmaceuticals
Phase 2
Recruiting
116 enrolled